Herceptin, Trastuzumab News

British Pharmaceutical company GlaxoSmithKline PLC announced the results of a clinical study Friday which found that women with an aggressive form of breast cancer known as HER2-positive disease reported a median survival of 14 months when using a oean investigational combination of TYKERBR plus HERCEPTINR ". "The clinical benefits brought forth by ...

Cancer treatment remains broadly reliant on three rather blunt instruments. A tumour can be cut out with a scalpel, burnt away with radiation, or poisoned with chemotherapy.

Washington, December 12 : Targeted therapy is more effective in cases of HER2-positive breast cancer, according to experts.

A new targeted cancer drug has been shown to shrink tumors in women with metastatic breast cancer after an average of seven other drugs, including Herceptin , failed.

An eye-opening overall response rate of 32.7 percent in Phase II trials with antibody-drug conjugate TDM-1 in last-resort breast cancer patients left investors in ImmunoGen Inc.

Genentech, Inc., a wholly owned member of the Roche Group , today announced positive results from a Phase II study of trastuzumab-DM1 . As assessed by independent review, T-DM1 shrank the tumors in 33 percent of women with advanced HER2-positive breast cancer that had worsened following previous treatment.

New research suggests that certain breast cancer patients who take the drug Herceptin during chemotherapy, instead of taking it afterward, fare better, leading one of the study authors to say patients should routinely take the drug with chemo.

ImmunoGen, Inc. , a biopharmaceutical company that develops targeted anticancer therapeutics, today announced the presentation of positive trastuzumab-DM1 clinical data at the 32nd Annual San Antonio Breast Cancer Symposium .

Array BioPharma Inc. today announced positive interim results of its novel, small molecule HER2 inhibitor, ARRY-380, in a Phase 1 trial in advanced cancer patients.

With a growing array of choices for breast cancer treatment, researchers are now trying to pinpoint the best combination of therapies or the best order in which to give cancer drugs to patients.

A new antibody-drug compound shrank or halted the growth of metastatic breast tumors in almost half of a group of patients whose HER2-positive cancer had become resistant to standard therapies, according to early data from a multicenter Phase 2 clinical trial led by a Dana-Farber Cancer Institute researcher.

A a oeguided missilea combination drug called T-DM1 developed by Roche Holding AG and Immunogen Inc.

Incyte Corporation announced today positive results from an ongoing Phase I/II clinical trial for its selective oral sheddase inhibitor, INCB7839, involving 46 patients with HER2 positive metastatic breast cancer.

As scientists and clinicians continue to uncover new information about breast cancer, the landscape of acceptable treatment and management continues to shift.

In a clinical study, women with an aggressive form of breast cancer experienced a median survival of 14 months when treated with an investigational combination of TYKERB plus HERCEPTIN .

Roche announced today that new 5 year follow-up data from two pivotal studies with Herceptin in early breast cancer; key results from a study of Avastin in the second-line treatment of advanced breast cancer and strong data on the use of trastuzumab-DM1 , the first antibody-drug conjugate in development for very advanced HER2-positive breast ...

Herceptin is the brand name of a medicine called trastuzumab . This medicine can stop the growth of breast cancer and sometimes reduce the size of the tumor.

Roche Holding AG said on Wednesday three studies on its drugs used to treat early and advanced breast cancer showed good results.

E-mail: kulkars@ccf.org Received 10 December 2008; Revised 25 September 2009; Accepted 13 October 2009; Published online 30 November 2009.

FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab.